Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A Brief But Memorable Tenure: Former US FDA Commissioner Lester Crawford Dies At 83

Executive Summary

Crawford’s time as permanent FDA commissioner lasted less than three months and ended in scandal, but with that stint and his longer stretches as acting commissioner, he oversaw the agency through several historic moments that continue to influence the current regulatory environment.

You may also be interested in...



Life After White Oak: Hamburg’s Predecessors Offer Glimpse At Where Pharma Might See Her Again

In interviews with “The Pink Sheet,” the last half-dozen FDA commissioners discuss crafting policy on Capitol Hill, building start-up biotechs, consulting and serving on industry boards.

FDA and Cancer Drug Development: An Advocate's View

Friends of Cancer Research (www.focr.org) has been among the most vocal supporters of a robust FDA review process for oncology drugs. Chair & Founder Dr. Ellen Sigal has taken the advocacy group from a one-person shop to an organization with strong ties to the agency and the lawmakers on Capitol Hill who matter most to the future of cancer treatment.

Ex-FDA Chief Crawford Calls For Dramatic Changes In Global Harmonization

A new global organization should be established to promote the harmonization of regulatory requirements between countries, according to former FDA Commissioner Lester Crawford

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS145509

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel